General

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Citrin R et al. Expert Rev Hematol. 2016 Jul 22. [Epub ahead of print]. A new era of immune therapy in multiple myeloma. Tai YT et al. Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a “real-world” study: the Royal Marsden…

Details

Complications of myeloma and its treatments

Assessment of Bone Fragility in Patients with Multiple Myeloma Using QCT-Based Finite Element Modelling. Campbell GM et al. J Bone Miner Res. 2016 Jul 25. doi: 10.1002/jbmr.2924. [Epub ahead of print]. Intracranial Involvement by Plasma Cell Neoplasms. Wilberger AC et al. Am J Clin Pathol. 2016 Jul 24. pii: aqw058. [Epub ahead of print]. Upper Gastrointestinal Bleeding Due to Amyloidosis in a Patient…

Details

Current treatments

Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. Jung SH et al. Ann Hematol. 2016 Jul 1. [Epub ahead of print]. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma. Jantunen E et al. Expert Rev Hematol. 2016 Jul 15:1-10. [Epub ahead of print]. Peripheral blood stem cells collection…

Details

Diagnostic tests and prognostic indicators

Bone mineral density utilization in patients with newly diagnosed multiple myeloma. Muchtar E et al. Hematol Oncol. 2016 Jun 21. doi: 10.1002/hon.2303. [Epub ahead of print]. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. D’Souza A et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14170. [Epub ahead of print].…

Details

Related conditions

The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications. Hemminki K et al. Sci Rep. 2016 Jun 22;6:28500. doi: 10.1038/srep28500. Next generation sequencing identifies a transcriptional profile that segues with genomic alterations in Waldenström macroglobulinemia. Hunter ZR et al. Blood. 2016 Jun 14. pii: blood-2016-03-708263. [Epub ahead of print]. Short- and long-term outcomes…

Details

Emerging treatments

Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Raje N et al. Clin Cancer Res. 2016 Jun 10. pii: clincanres.0201.2016. [Epub ahead of print]. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Lesokhin AM et al. J Clin Oncol. 2016 Jun 6. pii:…

Details

Biology and genetics

HIF-1α and rapamycin act as genosuppressant in multiple myeloma cells upon genotoxic stress. Coudre C et al. Cell Cycle. 2016 Jun 24:0. [Epub ahead of print]. CA-125 secreting IgG kappa Multiple Myeloma (MM). Boota M et al. Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24456. [Epub ahead of print]. To B(ortezomib) or Not to B: The Stroma’s the Thing. Krem MM et al. J Pathol. 2016 Jun 24.…

Details